Paper Details

  1. Home
  2. Paper Details

Pharmacokinetics and Safety of Intravenous and Subcutaneous Auto-injector Single-dose Belimumab in Healthy Chinese Volunteers: A phase 1, Randomized, Open-label Study.

Author: FangSun, LuHongzhou, MengXianmin, PuDi, WangQianqian, WuShunquan, ZhangAmber, ZhouXuan

Journal ArticleAn article published in an academic or professional journal that reports original research or scholarly analysis.

Overview

Belimumab is a monoclonal antibody used to treat systemic lupus erythematosus (SLE). This phase 1 study investigated the pharmacokinetics, safety, and tolerability of subcutaneous belimumab 200 mg in a healthy Chinese population.
Paper Details　
Original Abstract of the Article :
Belimumab is a recombinant human immunoglobulin G1λ monoclonal antibody indicated as an intravenous (IV) 10 mg/kg and subcutaneous (SC) 200-mg dose for the treatment of systemic lupus erythematosus (SLE). Belimumab 10 mg/kg IV has been approved for the treatment of patients with SLE in China. This p...See full text at original site
Dr.Camel IconDr.Camel's Paper Summary Blogラクダ博士について

ラクダ博士は、Health Journal が論文の内容を分かりやすく解説するために作成した架空のキャラクターです。
難解な医学論文を、専門知識のない方にも理解しやすいように、噛み砕いて説明することを目指しています。

* ラクダ博士による解説は、あくまで論文の要点をまとめたものであり、原論文の完全な代替となるものではありません。詳細な内容については、必ず原論文をご参照ください。
* ラクダ博士は架空のキャラクターであり、実際の医学研究者や医療従事者とは一切関係がありません。
* 解説の内容は Health Journal が独自に解釈・作成したものであり、原論文の著者または出版社の見解を反映するものではありません。


引用元：
https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8572285/

データ提供：米国国立医学図書館（NLM）

Belimumab: Exploring New Avenues for Systemic Lupus Erythematosus Treatment

Systemic lupus erythematosus (SLE), an autoimmune disease, can cause a range of symptoms and complications. This study investigates the pharmacokinetics and safety of belimumab, a monoclonal antibody used to treat SLE, in healthy Chinese volunteers. The researchers compared the intravenous (IV) and subcutaneous (SC) administration of belimumab, evaluating its absorption, distribution, metabolism, and elimination. Their findings suggest that both IV and SC administration of belimumab are well-tolerated and demonstrate favorable pharmacokinetic profiles. This research provides valuable data for optimizing the use of belimumab in the treatment of SLE.

Optimizing Treatment Strategies

The study's findings provide valuable insights into the pharmacokinetics and safety of belimumab, paving the way for optimizing its use in SLE treatment. The researchers' data suggest that both IV and SC administration are effective and well-tolerated, offering flexibility in treatment delivery. This research contributes to the development of more effective and convenient treatment options for individuals with SLE.

Understanding SLE: A Complex Puzzle

SLE is a complex autoimmune disease that can manifest in a variety of ways. This study underscores the importance of ongoing research and development in the field of SLE treatment, exploring new medications and optimizing existing therapies. By understanding the complexities of SLE and embracing new treatment approaches, we can work towards improving the lives of individuals affected by this challenging condition.

Dr.Camel's Conclusion

Just as a camel navigates a complex desert landscape, managing SLE requires a careful and nuanced approach. This research highlights the potential of belimumab to offer an effective and well-tolerated treatment option for SLE, providing hope for a better future for those living with this challenging condition.

Date :
  1. Date Completed n.d.
  2. Date Revised 2022-08-09
Further Info :

Pubmed ID

34554352

DOI: Digital Object Identifier

PMC8572285

SNS
PICO Info
in preparation
Languages

English

Positive IndicatorAn AI analysis index that serves as a benchmark for how positive the results of the study are. Note that it is a benchmark and requires careful interpretation and consideration of different perspectives.

This site uses cookies. Visit our privacy policy page or click the link in any footer for more information and to change your preferences.